KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation and Depletion (2016 - 2021)

Arbutus Biopharma's Depreciation and Depletion history spans 7 years, with the latest figure at $427000.0 for Q4 2021.

  • For Q4 2021, Depreciation and Depletion fell 12.32% year-over-year to $427000.0; the TTM value through Dec 2021 reached $1.8 million, down 11.38%, while the annual FY2024 figure was $1.4 million, 1.43% down from the prior year.
  • Depreciation and Depletion for Q4 2021 was $427000.0 at Arbutus Biopharma, down from $447000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $620000.0 in Q4 2017 and bottomed at $334000.0 in Q1 2017.
  • The 5-year median for Depreciation and Depletion is $490000.0 (2020), against an average of $484235.3.
  • The largest annual shift saw Depreciation and Depletion soared 103.78% in 2017 before it fell 15.45% in 2019.
  • A 5-year view of Depreciation and Depletion shows it stood at $620000.0 in 2017, then dropped by 2.9% to $602000.0 in 2018, then crashed by 41.69% to $351000.0 in 2019, then soared by 38.75% to $487000.0 in 2020, then fell by 12.32% to $427000.0 in 2021.
  • Per Business Quant, the three most recent readings for ABUS's Depreciation and Depletion are $427000.0 (Q4 2021), $447000.0 (Q3 2021), and $436000.0 (Q2 2021).